person in blue shirt showing left hand

Brussles, Belgium — UCB said Thursday the US Food and Drug Administration (FDA) agreed to consider approving the drug BIMZELX for treating two additional health conditions, including severe Hidradenitis Suppurativa. This follows earlier requests to use the drug for other types of arthritis. BIMZELX was originally approved in the U.S. in 2023 to treat a serious skin condition in adults.

The applications are based on Phase 3 studies showing improvements over placebos, UCB said. The goal is to expand treatment options for patients.

Severe Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by the presence of painful, deep-seated nodules and abscesses, primarily in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. In its severe form, HS can lead to extensive, interconnected tunnels known as sinus tracts or fistulas under the skin, and large, scarring lumps. These lesions can cause significant pain, discomfort, and drainage of pus, severely impacting the patient’s quality of life.

The exact cause of HS is not fully understood, but it involves a combination of genetic, environmental, and immune system factors. Treatment often includes antibiotics, hormonal therapy, and immunosuppressants, and in some cases, surgery may be necessary to remove the affected skin areas. Severe HS can also have a profound psychological impact, leading to depression and social isolation due to its symptoms and the stigma associated with the condition.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner